🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

James Ohr

ORCID: 0000-0002-7037-6404

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “The impact of tumor hypoxia on the clinical efficacy of anti-PD-1 mAb treatment in recurrent/metastatic HNSCC patients (R/M).”.

The impact of tumor hypoxia on the clinical efficacy of anti-PD-1 mAb treatment in recurrent/metastatic HNSCC patients (R/M).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.6546

N/A

0.515DataRank · unranked

10 citations

Maria A. Velez, Ashley V. Menk, Angen Liu, Heath D. Skinner, Umamaheswar Duvvuri +7 more

Phase Ib study of berzosertib, carboplatin, gemcitabine, and pembrolizumab in patients with squamous nonsmall lung cancer (ETCTN 10313)

The Oncologist(2025)10.1093/oncolo/oyaf373

N/A

0.109DataRank · unranked

1 citations

Benjamin Schluger, Hong Wang, James Ohr, Daniel P. Petro, Alexander D. Fuld +10 more

Phase II trial of adjuvant de-escalated radiation + adjuvant nivolumab for intermediate-high risk P16+ oropharynx cancer.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.6014

N/A

0.104DataRank · unranked

1 citations

Dan P. Zandberg, Adam Raben, Shaum Sridharan, Mark Kubik, José P. Zevallos +6 more